What is Innovative Cellular Therapeutics?
Innovative Cellular Therapeutics (ICT) operates at the forefront of the clinical-stage biotechnology landscape, specializing in the development of next-generation CAR-T therapies. By leveraging proprietary platforms such as CoupledCAR and INSTACAR, the company is actively addressing the complex challenges associated with treating solid tumors. Their lead candidate, GCC19CART, represents a significant milestone in the pursuit of effective treatments for relapsed or refractory metastatic colorectal cancer. Furthermore, the integration of the ARMORED CAR platform demonstrates the firm's commitment to enhancing the efficacy and safety profiles of cellular immunotherapies, aiming to redefine the standard of care for patients worldwide.
How much funding has Innovative Cellular Therapeutics raised?
Innovative Cellular Therapeutics has raised a total of $28.6M across 1 funding round:
Other Financing Round
$28.6M
Other Financing Round (2019): $28.6M with participation from LH Ventures
Key Investors in Innovative Cellular Therapeutics
LH Ventures
A venture capital firm focused on identifying and supporting high-growth potential companies within the life sciences and biotechnology sectors.
What's next for Innovative Cellular Therapeutics?
With this major strategic investment, Innovative Cellular Therapeutics is poised to transition its core candidates through critical clinical milestones. The capital will likely be deployed to expand the company's CAR-T candidate portfolio, specifically targeting a broader range of solid tumors that have historically proven resistant to conventional therapies. By scaling its operational capacity and refining its immunotherapy platforms, ICT is well-positioned to navigate the regulatory landscape and advance its mission of delivering transformative cancer treatments. Future growth will depend on the successful execution of ongoing clinical trials and the continued validation of their proprietary technology in diverse patient populations.
See full Innovative Cellular Therapeutics company page
